2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Antonio Tito Fojo, MD, PhD, discusses What Is the Minimal Trial Design for Drug Approval in Rare Cancers? during Economic and Regulatory Implications in Drug Development for Sarcoma and Rare Cancers: The Identification of Value and Quality

Antonio Tito Fojo, MD, PhD, discusses What Is the Minimal Trial Design for Drug Approval in Rare Cancers? during Economic and Regulatory Implications in Drug Development for Sarcoma and Rare Cancers: The Identification of Value and Quality

Chicago, IL - 2016 ASCO Annual Meeting - Antonio Tito Fojo, MD, PhD, discusses What Is the Minimal Trial Design for Drug Approval in Rare Cancers? during Economic and Regulatory Implications in Drug Development for Sarcoma and Rare Cancers: The Identification of Value and Quality at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Monday, June 6, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Max Gersh 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org